10 research outputs found
Pleiotropic strategies at the acute phase of ischemic stroke : pharmacological modulation by atorvastatin
Lâaccident vasculaire cĂ©rĂ©bral ischĂ©mique reste un problĂšme majeur de santĂ© publique, contre lequel lâarsenal thĂ©rapeutique reste trĂšs limitĂ©. Lâatorvastatine (AT), utilisĂ©e en prĂ©vention cardiovasculaire, possĂšde des effets plĂ©iotropes lui confĂ©rant un pouvoir protecteur dans lâAVC. Les objectifs de cette thĂšse Ă©taient dâĂ©valuer et de caractĂ©riser les effets neuro- et vasculoprotecteurs de lâAT dans lâischĂ©mie cĂ©rĂ©brale, et la part jouĂ©e par le rĂ©cepteur nuclĂ©aire PPARα. Des souris C57BL/6J sauvages et KO-PPARα ont Ă©tĂ© soumises Ă ischĂ©mie-reperfusion (I/R) cĂ©rĂ©brale. Elles Ă©taient traitĂ©es par AT prĂ©ventivement pendant 14 jours ou aprĂšs I/R pendant 24 ou 72 heures. Lâeffet neuroprotecteur est Ă©valuĂ© histologiquement et par des tests fonctionnels moteurs. Lâeffet vasculoprotecteur est Ă©valuĂ© sur lâartĂšre cĂ©rĂ©brale moyenne par Ă©tude de la fonction endothĂ©liale et sur les microvaisseaux cĂ©rĂ©braux par Ă©tude de leur structure et des interactions leucocytes-endothĂ©lium. Le traitement prĂ©ventif et aigu par AT induit une diminution du volume lĂ©sionnel, et une amĂ©lioration de la rĂ©cupĂ©ration fonctionnelle chez les animaux traitĂ©s Ă la phase aiguĂ«. Le traitement aigu permet de prĂ©server la fonction endothĂ©liale et lâintĂ©gritĂ© des microvaisseaux cĂ©rĂ©braux, et de limiter les interactions leucocytes-endothĂ©lium. PPARα est nĂ©cessaire aux effets neuro- et vasculoprotecteurs de lâAT dans lâischĂ©mie cĂ©rĂ©brale. Ce travail met en Ă©vidence lâintĂ©rĂȘt de lâatorvastatine en tant quâagent neuroprotecteur plĂ©iotrope dans lâischĂ©mie cĂ©rĂ©brale.Ischemic stroke still is a heavy public health burden, as effective therapeutic means remain scarce. Atorvastatin (AT), widely used as a preventive treatment in the cardiovascular field, possesses pleiotropic effects that give it protective properties in stroke. The goals of this work were to assess and characterize the neuro- and vasculoprotective effects of AT in cerebral ischemia, and the part played by PPARα. Wild-type and PPARα-KO C57BL/6J mice were submitted to cerebral ischemia-reperfusion (I/R). They were treated with AT before I/R for 14 days or acutely after I/R for 24 or 72 hours. Neuroprotection is assessed histologically and by a motor functional evaluation. Vasculoprotection is assessed on the middle cerebral artery by evaluating the endothelial function and on cerebral microvessels by evaluating their structure and the interactions between leukocytes and the vascular wall. Preventive and acute treatments with AT induce a reduction in lesion volumes, functional recovery was improved in acutely treated animals. The acute treatment with AT preserves the endothelial function and the microvascular integrity, and reduces the interactions between leukocytes and the endothelium. PPARα is necessary for AT neuro- and vasculoprotective effects to take place. This works highlights the interest of atorvastatin as a pleiotropic neuroprotective agent in ischemic stroke
IntĂ©rĂȘt des approches plĂ©iotropes dans l'ischĂ©mie cĂ©rĂ©brale : modulation pharmacologique par l'atorvastatine
Ischemic stroke still is a heavy public health burden, as effective therapeutic means remain scarce. Atorvastatin (AT), widely used as a preventive treatment in the cardiovascular field, possesses pleiotropic effects that give it protective properties in stroke. The goals of this work were to assess and characterize the neuro- and vasculoprotective effects of AT in cerebral ischemia, and the part played by PPARα. Wild-type and PPARα-KO C57BL/6J mice were submitted to cerebral ischemia-reperfusion (I/R). They were treated with AT before I/R for 14 days or acutely after I/R for 24 or 72 hours. Neuroprotection is assessed histologically and by a motor functional evaluation. Vasculoprotection is assessed on the middle cerebral artery by evaluating the endothelial function and on cerebral microvessels by evaluating their structure and the interactions between leukocytes and the vascular wall. Preventive and acute treatments with AT induce a reduction in lesion volumes, functional recovery was improved in acutely treated animals. The acute treatment with AT preserves the endothelial function and the microvascular integrity, and reduces the interactions between leukocytes and the endothelium. PPARα is necessary for AT neuro- and vasculoprotective effects to take place. This works highlights the interest of atorvastatin as a pleiotropic neuroprotective agent in ischemic stroke.Lâaccident vasculaire cĂ©rĂ©bral ischĂ©mique reste un problĂšme majeur de santĂ© publique, contre lequel lâarsenal thĂ©rapeutique reste trĂšs limitĂ©. Lâatorvastatine (AT), utilisĂ©e en prĂ©vention cardiovasculaire, possĂšde des effets plĂ©iotropes lui confĂ©rant un pouvoir protecteur dans lâAVC. Les objectifs de cette thĂšse Ă©taient dâĂ©valuer et de caractĂ©riser les effets neuro- et vasculoprotecteurs de lâAT dans lâischĂ©mie cĂ©rĂ©brale, et la part jouĂ©e par le rĂ©cepteur nuclĂ©aire PPARα. Des souris C57BL/6J sauvages et KO-PPARα ont Ă©tĂ© soumises Ă ischĂ©mie-reperfusion (I/R) cĂ©rĂ©brale. Elles Ă©taient traitĂ©es par AT prĂ©ventivement pendant 14 jours ou aprĂšs I/R pendant 24 ou 72 heures. Lâeffet neuroprotecteur est Ă©valuĂ© histologiquement et par des tests fonctionnels moteurs. Lâeffet vasculoprotecteur est Ă©valuĂ© sur lâartĂšre cĂ©rĂ©brale moyenne par Ă©tude de la fonction endothĂ©liale et sur les microvaisseaux cĂ©rĂ©braux par Ă©tude de leur structure et des interactions leucocytes-endothĂ©lium. Le traitement prĂ©ventif et aigu par AT induit une diminution du volume lĂ©sionnel, et une amĂ©lioration de la rĂ©cupĂ©ration fonctionnelle chez les animaux traitĂ©s Ă la phase aiguĂ«. Le traitement aigu permet de prĂ©server la fonction endothĂ©liale et lâintĂ©gritĂ© des microvaisseaux cĂ©rĂ©braux, et de limiter les interactions leucocytes-endothĂ©lium. PPARα est nĂ©cessaire aux effets neuro- et vasculoprotecteurs de lâAT dans lâischĂ©mie cĂ©rĂ©brale. Ce travail met en Ă©vidence lâintĂ©rĂȘt de lâatorvastatine en tant quâagent neuroprotecteur plĂ©iotrope dans lâischĂ©mie cĂ©rĂ©brale
Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach
AbstractSeveral observational studies have found a link between the long-term use of benzodiazepines and dementia, which remains controversial. Our study was designed to assess (i) whether the long-term use of benzodiazepines, at two different doses, has an irreversible effect on cognition, (ii) and whether there is an age-dependent effect. One hundred and five C57Bl/6 male mice were randomly assigned to the 15âmg/kg/day, the 30âmg/kg/day diazepam-supplemented pellets, or the control group. Each group comprised mice aged 6 or 12 months at the beginning of the experiments and treated for 16 weeks. Two sessions of behavioral assessment were conducted: after 8 weeks of treatment and after treatment completion following a 1-week wash-out period. The mid-treatment test battery included the elevated plus maze test, the Y maze spontaneous alternation test, and the open field test. The post-treatment battery was upgraded with three additional tests: the novel object recognition task, the Barnes maze test, and the touchscreen-based paired-associated learning task. At mid-treatment, working memory was impaired in the 15âmg/kg diazepam group compared to the control group (pâ=â0.005). No age effect was evidenced. The post-treatment assessment of cognitive functions (working memory, visual recognition memory, spatial reference learning and memory, and visuospatial memory) did not significantly differ between groups. Despite a cognitive impact during treatment, the lack of cognitive impairment after long-term treatment discontinuation suggests that benzodiazepines alone do not cause irreversible deleterious effects on cognitive functions and supports the interest of discontinuation in chronically treated patients
Effects of acute ethanol and/or diazepam exposure on immediate and delayed hippocampal metabolite levels in rats anesthetized with isoflurane.
International audienceAlcohol and benzodiazepines are psychoactive substances frequently associated in voluntary drug intoxications that share common mechanisms of action, including facilitation of GABAergic transmission. This study aimed to assess the separate and combined effects of ethanol and diazepam acute exposure on hippocampal metabolite levels, as well as on delayed cognitive performance, in rats anesthetized with isoflurane. Adult male Wistar rats received one intraperitoneal injection containing either saline solution (âCTLâ group, Nâ=â15), a 5-mg/kg dose of diazepam (âDIAâ group, Nâ=â16), a 2-g/kg dose of ethanol (âEtOHâ group, Nâ=â18), or a 5-mg/kg dose of diazepam + a 2-g/kg dose of ethanol (âDIAâ+âEtOHâ group, Nâ=â24). The levels of brain metabolites in the hippocampal region were assessed using in vivo magnetic resonance spectroscopy (MRS) before and after injection. Behavioral testing, including working memory and visual recognition memory assessment, was performed at week 3, while a new MRS acquisition was conducted 4âweeks after the injection. In the hour following acute exposure, a decrease in glutamate levels was found in the DIAâ+âEtOH group only. Four weeks after injection, a decrease in GABA and glutamate levels and an increase in NAA levels were found in the EtOH group only. No significant between-group differences were found in the behavioral assessment. While the initial decrease in glutamate levels in the DIAâ+âEtOH group suggests an early potentiation effect between ethanol and diazepam, the long-term modifications found only in the EtOH group suggest a possible downregulation of ethanol's effect by diazepam at 4 weeks
Additional file 1 of Fosfomycin-induced agranulocytosis: a case report and review of the literature
Supplementary Material
Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis
International audienceImportance The benefits of prophylactic antibiotics for hospitalized patients with severe alcohol-related hepatitis are unclear. Objective To determine the efficacy of amoxicillin-clavulanate, compared with placebo, on mortality in patients hospitalized with severe alcohol-related hepatitis and treated with prednisolone. Design, Setting, and Participants Multicenter, randomized, double-blind clinical trial among patients with biopsy-proven severe alcohol-related hepatitis (Maddrey function score â„32 and Model for End-stage Liver Disease [MELD] score â„21) from June 13, 2015, to May 24, 2019, in 25 centers in France and Belgium. All patients were followed up for 180 days. Final follow-up occurred on November 19, 2019. Intervention Patients were randomly assigned (1:1 allocation) to receive prednisolone combined with amoxicillin-clavulanate (nâ=â145) or prednisolone combined with placebo (nâ=â147). Main Outcome and Measures The primary outcome was all-cause mortality at 60 days. Secondary outcomes were all-cause mortality at 90 and 180 days; incidence of infection, incidence of hepatorenal syndrome, and proportion of participants with a MELD score less than 17 at 60 days; and proportion of patients with a Lille score less than 0.45 at 7 days. Results Among 292 randomized patients (mean age, 52.8 [SD, 9.2] years; 80 [27.4%] women) 284 (97%) were analyzed. There was no significant difference in 60-day mortality between participants randomized to amoxicillin-clavulanate and those randomized to placebo (17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group [ P =â.33]; between-group difference, â4.7% [95% CI, â14.0% to 4.7%]; hazard ratio, 0.77 [95% CI, 0.45-1.31]). Infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group (29.7% vs 41.5%; mean difference, â11.8% [95% CI, â23.0% to â0.7%]; subhazard ratio, 0.62; [95% CI, 0.41-0.91]; P =â.02). There were no significant differences in any of the remaining 3 secondary outcomes. The most common serious adverse events were related to liver failure (25 in the amoxicillin-clavulanate group and 20 in the placebo group), infections (23 in the amoxicillin-clavulanate group and 46 in the placebo group), and gastrointestinal disorders (15 in the amoxicillin-clavulanate group and 21 in the placebo group). Conclusion and Relevance In patients hospitalized with severe alcohol-related hepatitis, amoxicillin-clavulanate combined with prednisolone did not improve 2-month survival compared with prednisolone alone. These results do not support prophylactic antibiotics to improve survival in patients hospitalized with severe alcohol-related hepatitis. Trial Registration ClinicalTrials.gov Identifier: NCT0228192
COMBINATION OF AMOXICILLIN/CLAVULANATE AND PREDNISOLONE IN SEVERE ALCOHOLIC HEPATITIS: RESULTS OF THE ANTIBIOCOR RANDOMIZED CONTROLLED TRIAL.
International audienc
COMBINATION OF AMOXICILLIN/CLAVULANATE AND PREDNISOLONE IN SEVERE ALCOHOLIC HEPATITIS: RESULTS OF THE ANTIBIOCOR RANDOMIZED CONTROLLED TRIAL.
International audienc
Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke
International audienceTo determine whether the ratio single chain (sc)/(sc + 2 chain [tc]) recombinant tissue plasminogen activator (rtPA) influences outcomes in patients with cerebral ischemia.METHODS:We prospectively included consecutive patients treated with IV rtPA for cerebral ischemia in 13 stroke centers and determined the sc/(sc + tc) ratio in the treatment administered to each patient. We evaluated the outcome with the modified Rankin Scale (mRS) at 3 months (prespecified analysis) and occurrence of epileptic seizures (post hoc analysis). We registered Outcome of Patients Treated by IV Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA (OPHELIE) under ClinicalTrials.gov identifier no. NCT01614080.RESULTS:We recruited 1,004 patients (515 men, median age 75 years, median onset-to-needle time 170 minutes, median NIH Stroke Scale score 10). We found no statistical association between sc/(sc + tc) ratios and handicap (mRS > 1), dependency (mRS > 2), or death at 3 months. Patients with symptomatic intracerebral hemorrhages had lower ratios (median 69% vs 72%, adjusted p = 0.003). The sc/(sc + tc) rtPA ratio did not differ between patients with and without seizures, but patients with early seizures were more likely to have received a sc/(sc + tc) rtPA ratio >80.5% (odds ratio 3.61; 95% confidence interval 1.26-10.34).CONCLUSIONS:The sc/(sc + tc) rtPA ratio does not influence outcomes in patients with cerebral ischemia. The capacity of rtPA to modulate NMDA receptor signaling might be associated with early seizures, but we observed this effect only in patients with a ratio of sc/(sc + tc) rtPA >80.5% in a post hoc analysis
Trial of Deferiprone in Parkinson's Disease
Background Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. Methods We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. Results A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. Conclusions In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks